There were no differences in age, BMI, gender, HDRS-24 scores before treatment, treatment days and other demographic characteristics between the effective-treatment and ineffective-treatment groups, there was significant difference in the reduction rate of HDRS-24 scores and HDRS-24 scores after treatment between the two groups (Table 2)
A 0.5mg vial is the better choice it yields 10 doses (0.5mg = 500mcg 50mcg = 10), lasting exactly 5 weeks at twice-weekly dosing, well within the refrigerated stability window and minimizing waste
Liu, PP., Xie, Y., Meng, XY
Liver cancer risk reduction may be partly explained by the antisteatotic and anti-inflammatory effects of GLP-1 RAs in patients with NAFLD or metabolic syndrome (Figure 5)
Larson today to schedule a consultation and take the next step toward more informed, sustainable progress